From: EGFR exon 20 insertion mutations in advanced non-small-cell lung cancer: current status and perspectives
Treatment (reference)
N
Line
ORR (%)
mPFS (months)
mOS (months)
Platinum-based chemotherapy [12]
105
1
19.2
6.4
NA
Platinum-based chemotherapy [13]
21
19.0
6.5
Platinum-based chemotherapy [14]
49
7.6
19.9
Pemetrexed-based chemotherapy [15]
77
41.6
5.5
25
